{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:29:54Z","timestamp":1790512194283,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T00:00:00Z","timestamp":1465430400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ganciclovir\u2010resistant cytomegalovirus (<jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content>\u2010R <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) is an emerging challenge among solid organ transplant (<jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content>) recipients. The literature suggests that about 1% of abdominal transplant recipients develop <jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content>\u2010R <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection. The epidemiology and outcome of <jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content>\u2010R <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content> recipients who have received alemtuzumab induction is not well described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>After Institutional Review Board approval, a single\u2010center, retrospective review of 2148 abdominal <jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content> recipients between January 2006 and July 2011 at our institution (<jats:italic>n<\/jats:italic> = 2148) was conducted to identify patients with proven or empirically treated <jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content>\u2010R <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>. Descriptive statistics on collected demographics, clinical course, and therapeutic outcomes were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 116 <jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content> recipient treated for <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>, 14 patients (12.1% of cases; 0.65% of all <jats:styled-content style=\"fixed-case\">SOT<\/jats:styled-content> patients) had proven or suspected <jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content>\u2010R <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>. Eight (50%) developed <jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content>\u2010R <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> while receiving valganciclovir (val<jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content>) prophylaxis. The remainder developed late\u2010onset disease, after having completed an average 212 days (range 83\u2013353) of prophylaxis. Resistance was clinically suspected an average of 103 days (range 10\u2013455) after <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection was initially identified; 10 patients had confirmed genotypic resistance. Foscarnet therapy was associated with resolution of <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> in 13.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Suboptimal dosing of val<jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content> is associated with development of <jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content>\u2010R <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>. Our observed rate of <jats:styled-content style=\"fixed-case\">GCV<\/jats:styled-content>\u2010R <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> in alemtuzumab\u2010induced patients is similar to rates seen to historical data for other induction agents.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12537","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T20:48:35Z","timestamp":1459630115000},"page":"390-395","source":"Crossref","is-referenced-by-count":61,"title":["Ganciclovir\u2010resistant cytomegalovirus infection in solid organ transplant recipients: a single\u2010center retrospective cohort study"],"prefix":"10.1111","volume":"18","author":[{"given":"P.G.","family":"Young","sequence":"first","affiliation":[{"name":"The Christ Hospital Infectious Diseases Physicians Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago School of Medicine Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Angarone","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Penugonda","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Stosor","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago Illinois USA"},{"name":"Division of Organ Transplantation Northwestern University Feinberg School of Medicine Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Ison","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Northwestern University Feinberg School of Medicine Chicago Illinois USA"},{"name":"Division of Organ Transplantation Northwestern University Feinberg School of Medicine Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/591532"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/590934"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-12-200512200-00005"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003774.pub3"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1086\/507337"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12006"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31821fad25"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00009-10"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000170"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1086\/382753"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2011.12.019"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00561-13"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300826"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000257923.69422.4d"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01067.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12349"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12537","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:27:37Z","timestamp":1695569257000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/tid.12537"],"URL":"https:\/\/doi.org\/10.1111\/tid.12537","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}